Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, 18 hours ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Albumin-bilirubin score a reliable predictor of long-term prognosis in CHB-LC

09 Aug 2019

The albumin-bilirubin (ALBI) score is an accurate predictor of long-term prognosis in patients with chronic hepatitis B-related liver cirrhosis (CHB-LC), a recent study has shown.

The study included 398 CHB-LC patients (median age, 50.0 years; 73.4 percent male) in whom the prognostic performance of ALBI score was assessed and compared to that of the Child-Turcotte-Pugh (CTP), model of end-stage liver disease (MELD) and MELD with sodium (MELD-Na) scores. The main outcome was liver-related mortality.

Participants with decompensated cirrhosis had significantly higher ALBI scores than those with compensated disease (–1.8 vs –2.6; p<0.001). Similar trends were reported for the CTP, MELD and MELD-Na scores, though only ALBI was consistently correlated with the presence of decompensating events, such as ascites, hepatic encephalopathy and oesophageal variceal bleeding.

The importance of ALBI was verified through multivariable Cox proportional hazard regression analysis, which identified the score as a significant predictor of mortality (hazard ratio, 3.151, 95 percent CI, 2.039–4.869; p<0.001).

As a predictive model, ALBI garnered an area under the receiver operating characteristic (AUROC) curve value of 0.700, which was comparable to that of CTP (AUROC, 0.731), MELD (AUROC, 0.677) and MELD-Na (AUROC, 0.683) for the prediction of 1-year liver-related mortality.

However, ALBI significantly outperformed both the MELD and MELD-Na scores for the prediction of 2-year (AUROC, 0.756 vs 0.655 and 0.662), 3-year (AUROC, 0.745 vs 0.629 and 0.646) and 5-year (AUROC, 0.767 vs 0.636 and 0.651) liver-related mortality. No such superiority over CTP score was reported.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, 18 hours ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.